Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

NanoTech Pharma Inc United States

NanoTech Pharma focus on nanomedicine formulation development, located in New Jersey USA since year 2018. We have rich experiences in liposome and nanocrystal drug delivery systems. Our pipelines include 2 ANDA and several 505(b)(2) drugs, some of which have filed patents and are moving up to commercial scale.
Website:
www.NanoTech-Pharma.com
Company Size (Fulltime employees)
1-10
Year of foundation
2018, 10 FTEs
Partnering Objectives
Please specify your partnering goal
Equity funding and pipeline co-development
Headquartner in China
No
Biotech/Pharma Category
Ms. Ruby Sun
Vice President of Business Development 
Functionality
Business Development

NeoProgen United States

Cardiac Focused Stem Cell /Secretome Exosome company . Immortalized cell line
Website:
Www.NeoProgen.com
Company Size (Fulltime employees)
1-10
Year of foundation
2018
Partnering Objectives
Please specify your partnering goal
Out license Assets
Headquartner in China
No
Assets Information 1
Neo3002|Immortalized cell line|Heart Failure / AKI|None yet
Biotech/Pharma Asset Stage
Mr. Bill Niland
CEO 
Functionality
Management

New.Fa.Dem. Srl Italy

New.Fa.Dem. searches the new partners worldwide for the distribution of its own products.
New.Fa.Dem, a manufacturing company based in Italy and is authorized by Italian Agency of Drugs.
Conducts activities like R&D, Manufacturing, Distribution of ethical drugs, medical devices and cosmetics with own brand or private labeling.
Manufacturing of Creams, Gels, liquid, powder and suppositories.
Three important certifications:
• ISO 9001: 2015 for compliance with international quality management standards;
• ISO 13485: 2016 for congruence with the legislation relating to the quality of medical devices;
• GMP COMPLIANCE for the possession of authorizations and licenses for the production of pharmaceutical products.
Possibility of manufacturing medical devices and cosmetics of the same form in the facility in the near future.
Successfully present in Europe, Middle East and North Africa.
ISO Certifications for compliance of international standards of Quality Management and rules on the quality of Medical Devices.
Website:
www.newfadem.it
Company Size (Fulltime employees)
51-200
Year of foundation
1971
Partnering Objectives
Please specify your partnering goal
Looking forward for entering into emerging markets either through Distribution agreements or Private Labeling agreements.
Headquartner in China
No
Biotech/Pharma Category
Assets Information 1
Lidocaine + Nifedipine|rectal cream|anal fissueres and haemorrhoids|Worldwide
Assets Information 2
Diclofenac|oral drops|pain relief|Worldwide
Biotech/Pharma Asset Stage
Maria Goncharova
BD Director 
Functionality
Business Development

Next Pharma Inc. Canada

Next Pharma Inc. (NPI) is a biotechnology company headquartered in Toronto, Canada, focused on developing and commercializing products for early detection, diagnosis, and monitoring of the recurrence of Cancer and COVID-19 disease.
NPI is headquartered in Toronto, Ontario, Canada and will globally distribute and commercialize its AABH based diagnostic tests. NPI’s diagnostic tests are regarded as revolutionary as they can help to diagnose cancer at an early stage using a blood serum with high sensitivity/high specificity, fast turnaround (within 7 hours), are relatively inexpensive and are non-invasive.
Website:
www.nextpharmainc.com
Company Size (Fulltime employees)
11-50
Year of foundation
2016
Partnering Objectives
Please specify your partnering goal
Shareholder, and/or Partnership, and /or Profit sharing
Headquartner in China
No
Medtech Category
Medtech Information 1
NPI-Cancer Detection Blood Test|ELISA Kit|Canada
Medtech Development Stage
Dr. MAHMOOD MAHMOOD
Aspartyl (Asparaginyl) β Hydroxylase (AABH), Cancer Biomarker, Companion Imaging, and Diagnostic Strategy 
Functionality
Management

Novartis China

Top MNC
Website:
www.Novartis.com
Partnering Objectives
Headquartner in China
No
Biotech/Pharma Category
Yan Pan
AD，Business development and Licensing 

NxR Biotechnologies GmbH Switzerland

NxR Biotechnologies is a boutique global consulting firm assisting life science companies and academic institutions conduct business development or investment initiatives. Particularly, NxR provides Looking for services for performing strategic, scientific, and commercial assessments; writing business plans; gathering competitive intelligence; and implementing entrepreneurship projects, partnership and in/Licensing-out of conventional or regenerative medicine products, and commercialization deals. Areas of focus encompass the pharmaceutical industry and the white biotechnology industry. In the pharmaceutical industry, NxR focuses on cell-based and gene-based therapeutics, nucleic acid therapeutics, and biologics, in oncology, neurodegenerative diseases, inflammation, and rare diseases. In the white biotechnology industry, areas of specialization comprise sustainable chemicals including biomass conversion, biofuels, and polymers, as well as high value-added fermentation products including amino acids, proteins, and pharmaceuticals. NxR's track record comprises projects with big pharmas, biotechs, generics companies, financial investors, CROs, academia, and start-ups.
Website:
https://www.nxrbiotechnologies.com/
Year of foundation
2011
Partnering Objectives
Headquartner in China
No
Alain VERTES
Managing Director 
Functionality
Management

OcuMedic, Inc. United States

Replace eye drops from FREEDOM drug releasing clear contact lens corneal bandage. The device has a 7 day wear time consistent with the standard of care recall after; cataract, LASIK surgery & corneal abrasion & non infectious Uveitis. Doctor puts device on and takes it off eliminating patient compliance problems with quicker healing with drug constantly treating the target tissue. 10 granted patents with FTO legal opinion. 10 mono and combo ophthalmic Dougs tested. Completed in vivo safety study. Letter and meeting being set with the US FDA for phase 1-2 clinical in January 2021.
Website:
www.OcuMedics.com
Company Size (Fulltime employees)
1-10
Year of foundation
2006
Partnering Objectives
Please specify your partnering goal
Investment regulatory CFDA, manufacturing & distribution
Headquartner in China
No
Mr. Keith Ignotz
President & CEO 
Functionality
Management

OncoMyx Therapeutics United States

OncoMyx Therapeutics is developing potentially best-in-class (multi-armed, IV/systemically-delivered, precision medicine) oncolytic immunotherapies based upon the myxoma virus (MYXV) platform, and we have demonstrated mechanism of action and combinatorial efficacy (tumor growth inhibition) when dosed IV with various checkpoint inhibitors in multiple animal models. Our company has the industry’s most experienced oncolytic virus (OV) development team and an experienced SAB, and CEO Steve Potts was previously an executive at Ignyta (acquired by Roche for $1.7B). OncoMyx raised a $25M series A in June 2019 to advance our lead preclinical program to IND, and among our investors are BIVF (exited OV investment ViraTx for $244M at preclinical stage in 2018) and Jonathan Lim (Ignyta CEO & current Erasca CEO). On the heels of presenting our preclinical data at SITC and announcing the appointment of Mirati CEO Chuck Baum as our new Chairperson, OncoMyx is seeking a $50M+ series B/crossover to prepare for an IPO and focus on a future transition into a clinical-stage organization. Pasted below are links to our SITC posters and some recent Fierce and BioSpace articles focused on our company.

https://www.oncomyx.com/oncomyx-announces-presentation-of-preclinical-efficacy-data-of-novel-oncolytic-immunotherapy-at-sitc-2020/
https://www.fiercebiotech.com/research/arming-rabbit-pox-virus-to-fight-cancer
https://www.biospace.com/article/oncomyx-s-oncolytic-virus-platform-shows-preclinical-efficacy-boosting-immunotherapy-potential/

Website:
https://www.oncomyx.com
Company Size (Fulltime employees)
11-50
Year of foundation
2018
Partnering Objectives
Please specify your partnering goal
Fundraising and Licensing-out
Headquartner in China
No
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Slides Deck
(pdf, 2.38MB)
Dr. Steven Potts
Cofounder, CEO & Director 
Mr. Michael Wood
Cofounder, COO & CFO 
Functionality
Business Development
Dr. Leslie Sharp
Chief Scientific Officer 
Functionality
Research and Development

Otomagnetics United States

Otomagnetics is a biotechnology Company developing a non-invasive platform technology to deliver drugs and other therapeutic payloads to the inner and middle ear compartments, eye and skin. The link to the explainer video on the technology is provided below.

https://www.youtube.com/watch?v=1go9HYjMlFk&feature=youtu.be
Website:
http://www.otomagnetics.com/
Company Size (Fulltime employees)
1-10
Year of foundation
2012
Partnering Objectives
Please specify your partnering goal
Looking for partners focusing on ear disorders, macular degeneration and diabetic ulcers
Headquartner in China
No
Mrs. Abhita Batra
CEO 
Functionality
Management

Phagelux China

Phagelux is creating novel and best in class biological skin sciences products.
Website:
wwww.Phagelux.com
Company Size (Fulltime employees)
11-50
Year of foundation
2015
Partnering Objectives
Please specify your partnering goal
Global partners
Headquartner in China
Yes
Mr. Mark Engel
Chairman 
Functionality
Management